Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Khanna M, Rady H, Dai G, Ramsay AJ
Bacille-Calmette-Guerin (BCG) has variable efficacy as an adult tuberculosis (TB) vaccine but can reduce the incidence and severity of TB infection in humans. We have engineered modified vaccinia Ankara (MVA) strain vaccine constructs to express the secreted mycobacterial protein…
Professor Helen McShane, Professor Paul Moss
…linical challenge trial primarily to evaluate the safety of BCG challenge administered by the aerosol inhaled route in healthy, BCG naive UK adults. The trial will also look to evaluate and compare the amount of BCG recovered from the lungs and from the skin, following challenge …
Zhu B, Dockrell HM, Ottenhoff THM, Evans TG, Zhang Y
…serious disease around the world. Bacillus Calmette-Guérin (BCG) is the only TB vaccine licensed for use in human beings, and is effective in protecting infants and children against severe miliary and meningeal TB. However, BCG's protective efficacy is variable in adults. Novel T…
Kee Woong Kwon, Hongmin Kim, Hagyu Kim, Roland Brosch, Sung Jae Shin
Although Bacille Calmette-Guérin (BCG) protects children against disseminated tuberculosis (TB), its limited efficacy against adult pulmonary TB underscores the need for improved vaccination strategies. We previously developed a recombinant BCG strain expressing the ESX-1 ty…
Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, et al.
Background Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development. We aimed to assess whether the effectivenes…
Helen McShane, Gregory Hussey
This study is designed to evaluate the safety of the TB vaccine MVA85A in healthy children and infants in South Africa. A single vaccination with MVA85A has been shown to be safe and highly immunogenic in a wide range of subjects in previous clinical trials. In this trial,we will…
Christine M Qabar, Lucas Waldburger, Jay D Keasling, Dan A Portnoy, Jeffery S Cox
…urgent need to develop a more efficacious anti-tuberculosis vaccine as the current live-attenuated vaccine strain BCG fails to prevent pulmonary infection in adults. Our long-term goal is to test whether increasing the immunogenicity of BCG will improve vaccine effectiveness whil…
Yun JS, Kim SM, Lee JS, Jeong SH, Oh H, et al.
…ding cause of death worldwide. The Bacille Calmette-Guérin (BCG) vaccine, the only licensed TB vaccine, has insufficient protective efficacy in adults, necessitating the development of new TB vaccines. Ag85B, a protein-subunit TB vaccine, is a promising candidate due to its high …
Rakshit S, Ahmed A, Adiga V, Sundararaj BK, Sahoo PN, et al.
BACKGROUNDBacille Calmette-Guérin (BCG) vaccine is protective against Tuberculosis (TB) in children, but its efficacy wanes with age. Consequently, determining if BCG revaccination augments anti-TB immunity in young adults in TB endemic regions is vital.METHODSTwo hundred healthy…
M B Mouton, R M Horowitz, V M Limbert, L Bachnak, L A Morici, et al.
…ldwide. Intradermally administered Bacille Calmette-Guerin (BCG) is the only licensed Tb vaccine; however, BCG has limited efficacy in adults and vaccination site reactions. Additional issues include exclusion of immunocompromised/pregnant individuals, waning protection with age,…
Hao L, Wu Y, Zhang Y, Zhou Z, Lei Q, et al.
Bacillus Calmette-Guerin (BCG) is the only licensed vaccine to prevent children from tuberculosis (TB), whereas it cannot provide effective protection for adults. Our previous work showed a novel vaccine candidate, liposomal adjuvant DMT emulsified with a multistage antigen CMFO,…
Abiola Oduwole, JP Mwankon, Joseph Okebe, EB Esu, Moriam Chibuzor, et al.
Background: The Bacille Calmette-Guérin (BCG) vaccine, given as a single dose, offers variable protection against Tuberculosis (TB). It is plausible that repeat doses could improve the effectiveness of the BCG vaccine in settings where the population remain at risk of the disease…
Yang SJ, Chen YY, Hsu CH, Hsu CW, Chang CY, et al.
…to-eliminate disease. Although the Bacille Calmette-Guérin (BCG) vaccine against Mycobacterium tuberculosis (MTB) has been available for decades, its efficacy is variable and has lessened over time. Furthermore, the BCG vaccine no longer protects against newly emerged Beijing str…
Y. Su, Yin Cao, R L Wang, E J Dong, Weihong Zhao, et al.
Currently, Bacille Calmette-Guerin(BCG) is still the only admitted vaccine to prevent tuberculosis around the world. The target population is infants and children, but its protective efficacy is limited. As more and more studies have shown that re-vaccination with BCG protects ag…
Shah JA, Lindestam Arlehamn CS, Horne DJ, Sette A, Hawn TR
Development of an improved tuberculosis (TB) vaccine is a high worldwide public health priority. Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, provides variable efficacy against adult pulmonary TB, but why this protection varies is unclear. Humans are regularly ex…
Tangie E, Walters A, Hsu NJ, Fisher M, Magez S, et al.
…serious threats to global health. Bacillus Calmette-Guerin (BCG), the only licensed vaccine against TB protects against severe disseminated forms of TB in infants but shows poor efficacy against pulmonary TB in adults. Co-infections have been reported as one of the factors implic…
Jorge Barrios‐Payán, Cristian Alfredo Segura-Cerda, Dulce Mata‐Espinosa, Helle Bielefeldt‐Ohmann, Rogélio Hernández‐Pando, et al.
…cination with Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is effective in controlling severe forms of TB in childhood, with limited efficacy in preventing lung disease in adults, which is further reduced by infection with Beijing strains.We previously showed that a standar…
Aishwarya Shaji, Akanksha Verma, Ashima Bhaskar, Ved Prakash Dwivedi
…den. To assist in curbing the spread of TB, the century-old BCG, which is a live-attenuated vaccine, is now the only licensed TB vaccine used in humans. However, BCG's limited efficacy and poor antigenicity in adults have evoked the need to design new vaccines against TB. The lim…
Cotton MF, Madhi SA, Luabeya AK, Tameris M, Hesseling AC, et al.
…th problem worldwide. Immunisation with Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of miliary and tuberculosis meningitis, but is less effective against pulmonary tuberculosis. We aimed to compare safety and immunogenicity of VPM1002…
Jia Q, Masleša-Galić S, Nava S, Horwitz MA
… people and death in ~1.5 million people annually. A potent vaccine is needed to boost the level of immunity conferred by the current Mycobacterium bovis BCG vaccine that provides moderate protection against childhood TB but variable protection against adult pulmonary TB. Previou…
James CA, Yu KKQ, Mayer-Blackwell K, Fiore-Gartland A, Smith MT, et al.
Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used for 100 years and prevents disseminated tuberculosis and death in young children. However, it shows only partial efficacy against pulmonary tuberculosis (TB) in adults, so new vaccines are urgently needed. The protec…
Lacámara S, Martin C
…6 million deaths each year. Currently, the only approved TB vaccine in use in humans, is the one hundred years old vaccine, BCG, an attenuated vaccine derived from an isolate of Mycobacterium bovis that causes TB in cattle. BCG shows a variable efficacy in preventing pulmonary fo…
Mark Hatherill
…oject is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to HIV-infected and HIV-uninfected mothers as compared to standard of care BCG vaccinat…
Kulesza J, Kulesza E, Koziński P, Karpik W, Broncel M, et al.
Despite controversy over the protective effect of the BCG (Bacille Calmette-Guérin) vaccine in preventing pulmonary tuberculosis (TB) in adults, it has been used worldwide since 1921. Although the first reports in the 1930s had noted a remarkable decrease in child mortality after…
Foster M, Hill PC, Setiabudiawan TP, Koeken VACM, Alisjahbana B, et al.
The tuberculosis (TB) vaccine Bacillus Calmette-Guérin (BCG) was introduced 100 years ago, but as it provides insufficient protection against TB disease, especially in adults, new vaccines are being developed and evaluated. The discovery that BCG protects humans from becoming inf…